Ticagrelor Market Report 2026

Ticagrelor Market Overview

• Ticagrelor market size has reached to $1.93 billion in 2025 • Expected to grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Increasing Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Rising Risk Factors And Mortality Rates • Market Trend: Regulatory Approvals Drive Expansion Of Product Indications • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ticagrelor Market?

Ticagrelor is an oral antiplatelet medication primarily used to reduce the risk of stroke, heart attack, and other cardiovascular events in individuals with acute coronary syndrome (ACS) or a history of myocardial infarction. It works by inhibiting platelet aggregation, preventing blood clots from forming in arteries. This helps improve blood flow and reduces the likelihood of further cardiovascular events. The main types of ticagrelor are 90 mg tablets and 60 mg tablets. The 90 mg ticagrelor tablet is a prescription medication used to prevent blood clots in patients with acute coronary syndrome (ACS) or a history of heart attack. It belongs to several drug classes, including antiplatelet agents and antithrombotic agents, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Its key applications include the treatment of acute coronary syndrome, myocardial infarction, stroke prevention, and others, and it is utilized by various end users such as hospitals and clinics, ambulatory centers, and others.

What Is The Ticagrelor Market Growth Forecast?

The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to launch of extended-release ticagrelor tablets, expansion of retail and online pharmacy distribution, rising adoption of personalized cardiovascular treatment, increasing government initiatives for cardiovascular disease prevention, integration with digital health monitoring systems. Major trends in the forecast period include rising use of ticagrelor in acute coronary syndrome management, growing preference for oral antiplatelet therapy over injectable options, expansion of hospital and ambulatory cardiology services, increasing awareness of stroke and myocardial infarction prevention, development of extended-release ticagrelor formulations.

Global Ticagrelor Market Segmentation

1) By Type: 90 mg Tablet, 60 mg Tablet 2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications 5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users

What Is The Driver Of The Ticagrelor Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the ticagrelor market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. The increasing prevalence of cardiovascular diseases is primarily attributed to poor diet, as the excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels, all of which are major risk factors for heart-related conditions. Ticagrelor helps in treating cardiovascular diseases by preventing platelet aggregation, reducing the risk of blood clots. It improves patient outcomes by lowering the chances of heart attacks and strokes, especially in high-risk individuals. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ticagrelor industry.

Key Players In The Global Ticagrelor Market

Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.

Global Ticagrelor Market Trends and Insights

Major companies operating in the ticagrelor market are focusing on obtaining regulatory approvals to expand product indications, increase market access, and strengthen their competitive positioning. Regulatory approvals refer to the official permission granted by government authorities to market and sell a product, ensuring it meets safety, efficacy, and quality standards. For instance, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg and tentative approval for the 60 mg strength. These tablets are used to reduce the risk of cardiovascular events and work by inhibiting platelet aggregation, thereby preventing the formation of blood clots.

What Are Latest Mergers And Acquisitions In The Ticagrelor Market?

In May 2023, SERB Pharmaceuticals, a Luxembourg-based pharmaceutical company, partnered with SFJ Pharmaceuticals Inc. to advance the development of a ticagrelor reversal agent. This partnership focuses on advancing the development, obtaining U.S. regulatory approval, and commercializing bentracimab, a ticagrelor reversal agent, to quickly counteract ticagrelor's blood-thinning effects in patients needing urgent surgery or experiencing major bleeding. SFJ Pharmaceuticals Inc. is a US-based pharmaceutical company that offers ticagrelor reversal agents.

Regional Insights

North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ticagrelor Market?

The ticagrelor market consists of sales of branded oral tablets, generic ticagrelor formulations, fixed-dose combination products, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ticagrelor Market Report 2026?

The ticagrelor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ticagrelor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.